Spanish biotech Vytrus Biotech, has received a favourable report on its compliance with the requirements for incorporation from the Market & Incorporations Coordination Committee.
This means that it will be able to launch on the BME Growth stock market, which lists SMEs in Spain, within a few weeks.
The initial valuation is €12.2 million and the company’s shares will start trading with a reference value of €1.72/share once it has definitive approval of incorporation. Vytrus is specialised in active ingredients derived from plant stem cells for the cosmetic industry.
